Search
for
Sort by
Research 30 of 1000+
- A new tool for conditional gene manipulation in a subset of keratin‐expressing epithelia
- Olumiant® (Baricitinib)-A Newly Approved Janus Kinase Inhibitor for the Treatment of Alopecia Areata.
- Effect of camouflaging agents on psychologic well-being: A cross-sectional survey of hair loss patients
- Anabolic androgenic steroids and carcinogenicity focusing on Leydig cell: a literature review
- Acute exposure to hair bleach causes airway hyperresponsiveness in a rabbit model
- Östrogen-induzierte Gynäkomastie nach Anwendung östrogenhaltiger Lokaltherapeutika
- 76367 Prescribing Patterns of Androgenetic Alopecia Treatments in Transgender vs. Cisgender Patients: A Database Analysis
- 76221 Faster Onset and Superior Efficacy of an Investigational Extended-Release Oral Minoxidil Tablet (VDPHL01) Versus Topical and Immediate-Release Oral Minoxidil for Androgenetic Alopecia: Results from a Blinded Retrospective Investigator Global Assessment
- 74582 Early improvement in scalp hair regrowth with deuruxolitinib in patients with severe alopecia areata: Pooled analysis of the THRIVE-AA1 and THRIVE-AA2 Phase 3 trials
- 73571 The real-world impact of JAK inhibitor treatment on anxiety and depression outcomes and the role of eyebrow and eyelash hair regrowth in alopecia areata: TARGET-DERM
- Patient preferences for treatment characteristics of Janus kinase inhibitors for alopecia areata: a discrete choice experiment
- 75995 Social Listening Analysis of 143,000 Online Conversations on Hair Loss Treatments: Side Effects, Satisfaction, and Discontinuation
- Treatment patterns and healthcare resource utilization among patients with alopecia areata: A real‐world chart review in South Korea
- Multiple endocrine defects in adult-onset Sprouty1/2/4 triple knockout mice
- Severe Hypernatremia as Presentation of Netherton Syndrome
- Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b–3 trial
- Two Phase 3 Trials of Baricitinib for Alopecia Areata
- A preliminary observation: Male pattern hair loss among hospitalized COVID‐19 patients in Spain – A potential clue to the role of androgens in COVID‐19 severity
- The Alopecia Areata Investigator Global Assessment scale: a measure for evaluating clinically meaningful success in clinical trials
- Efficacy and safety of the oral Janus kinase inhibitor baricitinib in the treatment of adults with alopecia areata: Phase 2 results from a randomized controlled study
- Efficacy and safety of deuruxolitinib, an oral selective Janus kinase inhibitor, in adults with alopecia areata: Results from the Phase 3 randomized, controlled trial (THRIVE-AA1)
- Topical Janus kinase inhibitors: A review of applications in dermatology
- The use of oral pioglitazone in the treatment of lichen planopilaris
- Development of Clinician-Reported Outcome (ClinRO) and Patient-Reported Outcome (PRO) Measures for Eyebrow, Eyelash and Nail Assessment in Alopecia Areata
- Comorbidities in patients with alopecia areata
- New and Emerging Therapies for Alopecia Areata
- Hair: What is New in Diagnosis and Management?
- Clinical Efficacy of Diphenylcyclopropenone in Alopecia Areata: Retrospective Data Analysis of 50 Patients
- The Invisible Impact of a Visible Disease: Psychosocial Impact of Alopecia Areata
- Complementary and Alternative Treatments for Alopecia: A Comprehensive Review